$MeiraGTx Holdings (MGTX.US)$
MeiraGTx Receives Rare Pediatric Disease Designation from FDA for AAV8-RK-RetGC for the Treatment of Patients with Leber Congenital Amaurosis due to GUCY2D Mutations
MeiraGTx (NASDAQ: MGTX) has received Rare Pediatric Disease Designation (RPDD) from the FDA for its AAV8-RK-RetGC program, targeting Leber congenital amaurosis due to GUCY2D mutations (LCA1). This marks the company's fourth RPDD in three months, following designations for treatments of LCA4 retinal...

$MeiraGTx Holdings (MGTX.US)$ Reuters· 3 mins ago
MeiraGTx Receives Rare Pediatric Disease Designation From FDA for Aav8-Rk-Retgc for the Treatment of Patients With Leber Congenital Amaurosis Due to Gucy2D Mutations

$MeiraGTx Holdings (MGTX.US)$ Reuters· just
MeiraGTx Granted FDA Regenerative Medicine Advanced Therapy (Rmat) Designation for Aav2-Haqp1 for the Treatment of Grade 2/3 Radiation-Induced Xerostomia

$MeiraGTx Holdings (MGTX.US)$
MeiraGTx Announces Five Posters at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress
MeiraGTx Holdings plc (Nasdaq: MGTX) announced five poster presentations at the European Society of Gene and Cell Therapy (ESGCT) 2024 Annual Congress in Rome, Italy. The posters highlight the company's advancements in genetic medicine and cell therapy platforms:
1. Optimized AAV manufacturing platform yielding high titers and improved product quality.
2....

$MeiraGTx Holdings (MGTX.US)$
MeiraGTx Holdings | SC 13G/A: Statement of acquisition of beneficial ownership by individuals (Amendment)-Johnson & Johnson(8.6%),Johnson & Johnson Innovation-JJDC, Inc.(8.6%)

$Amazon (AMZN.US)$ breaking news big $Meiragtx Holdings Plc just cured Parkinson disease treatment 🔥🔥🔥👀 news today

$MeiraGTx Holdings (MGTX.US)$ Reuters· 3 mins ago
MeiraGTx Holdings PLC: Primary Study Objective of Safety and Tolerability Was Met

$MeiraGTx Holdings (MGTX.US)$ MeiraGTx Announces $50 Million Offering of Ordinary Shares Led by Sanofi’s 30M and Reports Second Quarter 2024 Financial and Operational Results